Merck Stock Dips Ahead of Key Earnings Report
Merck & Co. (ISIN US58933Y1055) saw its stock dip 2.90 percent on October 5, 2026, closing at USD 140.12 on the NYSE. The decline came ahead of the company's third-quarter earnings report, scheduled for October 29, 2026. Merck had previously announced this date on October 1, 2026, setting the stage for investor scrutiny following its second-quarter results, which showed sales of USD 16.61 billion, exceeding analyst expectations of USD 16.37 billion.
The company's revenue growth of 5.1 percent year-over-year has been a key metric, but analysts remain cautious about near-term upside. Sixteen analysts rate Merck a Buy, while eleven suggest Hold, resulting in a Moderate Buy consensus with an average price target of USD 146.36-4.45 percent above its October 5 price. JPMorgan, however, boosted its target to USD 165.00 from USD 150.00, maintaining an Overweight rating, which represents a 17.75 percent premium over the current stock price.
As of October 5, 2026, Merck's stock was trading within its 52-week range of USD 82.01 to USD 156.92, sitting 10.70 percent below its yearly high. The company's market capitalization stood at USD 346.1 billion, with a trading volume of 5,294,441 shares. Upcoming events include an investor meeting at ESMO 2026 on October 26, 2026, and the third-quarter earnings call on October 29, 2026.